Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Other financing activities (2017 - 2025)

Protagonist Therapeutics' Other financing activities history spans 9 years, with the latest figure at $2.8 million for Q4 2025.

  • For Q4 2025, Other financing activities fell 29.62% year-over-year to $2.8 million; the TTM value through Dec 2025 reached $23.3 million, down 11.76%, while the annual FY2025 figure was $23.3 million, 11.76% down from the prior year.
  • Other financing activities for Q4 2025 was $2.8 million at Protagonist Therapeutics, down from $5.7 million in the prior quarter.
  • Across five years, Other financing activities topped out at $12.1 million in Q3 2024 and bottomed at -$2.3 million in Q1 2023.
  • The 5-year median for Other financing activities is $2.4 million (2021), against an average of $3.3 million.
  • The largest annual shift saw Other financing activities tumbled 188.39% in 2023 before it skyrocketed 1080.31% in 2024.
  • A 5-year view of Other financing activities shows it stood at $2.3 million in 2021, then tumbled by 76.27% to $555000.0 in 2022, then fell by 6.49% to $519000.0 in 2023, then soared by 676.69% to $4.0 million in 2024, then dropped by 29.62% to $2.8 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Other financing activities are $2.8 million (Q4 2025), $5.7 million (Q3 2025), and $2.9 million (Q2 2025).